Related Experiment Video

Updated: Aug 2, 2026

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma

P Y Holoye1, D T Carr, H M Dhingra

  • 1Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.

Investigational New Drugs
|September 1, 1988
PubMed

Insights

Tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, showed no objective remission in patients with small cell lung cancer. Moderate toxicity was observed at the tested dosage.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Small cell lung cancer (SCLC) is an aggressive form of lung cancer.
  • Chemotherapy resistance is a significant challenge in SCLC treatment.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of tiazofurin in patients with advanced SCLC.
  • To determine if tiazofurin can induce objective remission in pre-treated SCLC patients.

Main Methods:

  • A phase II clinical trial was conducted.
  • Fourteen evaluable patients with SCLC received tiazofurin (800 mg/m2 daily for 5 days).
  • Patients had progressed after prior combination chemotherapy.

Main Results:

  • No objective remission was observed in any of the fourteen evaluable patients.
  • Tiazofurin was generally well-tolerated, with moderate toxicity reported.
  • The specific toxicities and their severity were not detailed in the abstract.

Conclusions:

  • Tiazofurin, at the tested dose and schedule, is not effective as a single agent for patients with pre-treated SCLC.
  • Further research may be needed to explore alternative dosing, combinations, or patient populations.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...